ClearOne Awarded Important New Patent for Beamforming Microphone Array Innovations
SALT LAKE CITY, July 29, 2020 (GLOBE NEWSWIRE) — ClearOne (NASDAQ: CLRO), a global provider of audio and visual communication […]
Sunesis Announces Pricing of $12 Million Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., July 29, 2020 (GLOBE NEWSWIRE) — Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the pricing of […]
David Evans, Chief Administrative Officer, announces retirement from Cardlytics
ATLANTA, July 29, 2020 (GLOBE NEWSWIRE) — Cardlytics, Inc., (NASDAQ: CDLX), an advertising platform in banks’ digital channels, announced today […]
ShiftPixy Introduces ShiftPixy Labs
IRVINE, Calif., July 29, 2020 (GLOBE NEWSWIRE) — ShiftPixy, Inc. (NASDAQ: PIXY), a California-based gig engagement platform provider, today announced […]
Peapack-Gladstone Financial Corporation Reports Second Quarter Results
Bedminster, N.J., July 29, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Peapack-Gladstone Financial Corporation (NASDAQ Global Select Market: PGC) (the […]
Natural Health Trends to Report Second Quarter 2020 Financial Results on August 5th
HONG KONG, July 29, 2020 (GLOBE NEWSWIRE) — Natural Health Trends Corp. (NASDAQ: NHTC), a leading direct-selling and e-commerce company […]
Fortinet Again Named the Fastest Growing SD-WAN Vendor, Continues Innovation to Deliver SD-WAN Anywhere
SUNNYVALE, Calif., July 29, 2020 (GLOBE NEWSWIRE) —John Maddison, EVP of products and CMO at Fortinet“With the increase in work […]
Hanmi Financial Declares Cash Dividend of $0.08 per Share
LOS ANGELES, July 29, 2020 (GLOBE NEWSWIRE) — Hanmi Financial Corporation (NASDAQ: HAFC) (“Hanmi”), the holding company for Hanmi Bank, […]
Usio Announces Transaction Processing Volume for the Second Quarter of 2020
Innovative New Prepaid Programs Drive 64% Increase in Load Volumes, 47% Increase in Transaction VolumesProduct Diversification Enables Continued Growth in […]
Denali Therapeutics Announces Phase 1b Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in COVID-19 Patients
Dosing of DNL758 (SAR443122) has commenced in a randomized, double-blind, placebo-controlled Phase 1b trial to evaluate safety and effect on […]
